



Advances in Chronic Lymphocytic Leukaemia (CLL) Research

Guest Editor:

Prof. Dr. H. Denis Alexander

Personalised Medicine Centre,
School of Medicine, Ulster
University, C-TRIC Building,
Altnagelvin Hospital,
Derry/Londonderry BT47 6SB,
Northern Ireland, UK

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Dear Colleagues,

Research activity in various aspects of CLL, including aetiology, the biology of the malignant cells, IGHV mutational status and gene usage, chromosomal and molecular aberrations, roles of flow cytometry and molecular investigations in defining complete remissions, and treatment strategies, including use of more targeted therapies and novel agents.

It seems timely to review progress towards answering questions raised by the original papers and whether these have provided a better understanding of the aetiology of CLL, whether pathogenic- or auto-antibodies are pivotal in initiation of the oncogenic transformation of normal B cells, and, most importantly, progress towards improved survival and a potential cure.

To mark the approaching 25th anniversary in 2024, *Cancers* (IF 6.575) now publish a Special Issue on CLL and invited me to act as Guest Editor. Original research and review are welcome.

Prof. Dr. H. Denis Alexander





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)